MX391040B - Formulacion de alta concentracion. - Google Patents

Formulacion de alta concentracion.

Info

Publication number
MX391040B
MX391040B MX2017017119A MX2017017119A MX391040B MX 391040 B MX391040 B MX 391040B MX 2017017119 A MX2017017119 A MX 2017017119A MX 2017017119 A MX2017017119 A MX 2017017119A MX 391040 B MX391040 B MX 391040B
Authority
MX
Mexico
Prior art keywords
high concentration
concentration formulation
formulation
cortexolone
present disclosure
Prior art date
Application number
MX2017017119A
Other languages
English (en)
Other versions
MX2017017119A (es
Inventor
Luigi Maria Longo
Original Assignee
Cassiopea S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53491322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX391040(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cassiopea S P A filed Critical Cassiopea S P A
Publication of MX2017017119A publication Critical patent/MX2017017119A/es
Publication of MX391040B publication Critical patent/MX391040B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente descripción proporciona formulaciones de alta concentración de 1 7a-propionato de cortexolona adecuadas para tratar la alopecia.
MX2017017119A 2015-06-22 2016-06-20 Formulacion de alta concentracion. MX391040B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562182988P 2015-06-22 2015-06-22
EP15173860.6A EP3108879A1 (en) 2015-06-25 2015-06-25 High concentration formulation
PCT/IB2016/053662 WO2016207778A1 (en) 2015-06-22 2016-06-20 High concentration formulation

Publications (2)

Publication Number Publication Date
MX2017017119A MX2017017119A (es) 2018-08-01
MX391040B true MX391040B (es) 2025-03-21

Family

ID=53491322

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017017119A MX391040B (es) 2015-06-22 2016-06-20 Formulacion de alta concentracion.

Country Status (22)

Country Link
US (6) US10603327B2 (es)
EP (3) EP3108879A1 (es)
JP (4) JP6916744B2 (es)
KR (1) KR102636936B1 (es)
CN (1) CN107979999B (es)
AU (1) AU2016284935B2 (es)
BR (1) BR112017027721A2 (es)
CA (1) CA2987701C (es)
DK (1) DK3310340T3 (es)
ES (1) ES3056907T3 (es)
FI (1) FI3310340T3 (es)
HR (1) HRP20251498T1 (es)
LT (1) LT3310340T (es)
MX (1) MX391040B (es)
PL (1) PL3310340T3 (es)
PT (1) PT3310340T (es)
RS (1) RS67597B1 (es)
RU (1) RU2731564C2 (es)
SI (1) SI3310340T1 (es)
SM (1) SMT202600032T1 (es)
WO (1) WO2016207778A1 (es)
ZA (1) ZA201708173B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation
CN115068423A (zh) * 2021-03-12 2022-09-20 浙江万晟药业有限公司 一种克拉司酮泡沫剂及其制备方法
CN113425845B (zh) * 2021-08-10 2022-12-02 成都倍特药业股份有限公司 一种预防和/或治疗脱发症的传递体制剂及其制备方法和用途
WO2024211282A1 (en) * 2023-04-07 2024-10-10 Amplifica Holdings Group, Inc. Compositions and methods for treatment of androgenetic alopecia
TW202444338A (zh) 2023-04-07 2024-11-16 義大利商卡斯歐皮亞股份公司 克拉司酮與米諾地爾之組合療法
EP4529925A1 (en) 2023-09-26 2025-04-02 Cassiopea S.p.A. Cortexolone-17-alpha- propionate for treating acneiform eruptions
WO2025068281A1 (en) 2023-09-26 2025-04-03 Cassiopea S.P.A. CORTEXOLONE-17α-PROPIONATE FOR TREATING ACNEIFORM ERUPTIONS
WO2025094021A1 (en) * 2023-10-31 2025-05-08 Lupin Limited Stable topical cream formulation of clascoterone
WO2025125508A1 (en) 2023-12-14 2025-06-19 Cassiopea S.P.A. Cortexolone-17αlpha-propionate combinations for treating acne
US20250213594A1 (en) * 2023-12-27 2025-07-03 Inventage Lab Inc. Novel long-acting injectable composition for preventing or treating androgenetic alopecia containing finasteride
WO2025172818A1 (en) 2024-02-14 2025-08-21 Cassiopea S.P.A. Pyrilutamide combination therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB791771A (en) 1954-07-29 1958-03-12 Merck & Co Inc Steroid compounds
US2985650A (en) 1958-05-28 1961-05-23 Syntex Sa 6alpha-ammonio-derivatives of 11-keto cortical hormones
DE1195748B (de) 1961-06-24 1965-07-01 Vismara Francesco Spa Verfahren zur Herstellung von 1'-substituierten 17alpha, 21-(1'-Alkoxy)-methylendioxysterioden
NL6605514A (es) 1966-04-25 1967-10-26
NL6605515A (es) 1966-04-25 1967-10-26
US3780177A (en) 1967-06-16 1973-12-18 Warner Lambert Co 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
US3733318A (en) 1972-03-23 1973-05-15 Syntex Corp 21-orthoesters of cortical steroids and methods of preparing same
JPS5910799B2 (ja) 1975-07-15 1984-03-12 大正製薬株式会社 プレグナン系ステロイド １７−エステル類の製法
DE3243482A1 (de) 1982-11-22 1984-05-24 Schering AG, 1000 Berlin und 4709 Bergkamen Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung
DE3402330A1 (de) 1984-01-20 1985-07-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US4920216A (en) 1987-05-28 1990-04-24 The Trustees Of Columbia In The City Of New York Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates
US5264428A (en) 1990-02-16 1993-11-23 Kanoldt Arzneimittel Gmbh Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
DE19653730C2 (de) 1996-12-11 1999-06-24 Schering Ag Immobilisierte Proteine aus Rohextrakt und deren Verwendung zur Umsetzung von Estern
EP0970948B1 (en) 1997-06-25 2005-03-09 Teijin Limited Vitamin d 3? derivatives and remedies for inflammatory respiratory diseases prepared from the same
ES2310886T3 (es) 2001-05-22 2009-01-16 Pfizer Products Inc. Nueva forma cristalina de azitromicina.
ITMI20011762A1 (it) 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
WO2004060347A2 (en) 2002-09-03 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003080042A1 (en) 2002-03-27 2003-10-02 Shionogi & Co., Ltd. Decomposition inhibitor for extracellular matrix of cartilage
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
WO2004014935A1 (de) 2002-08-02 2004-02-19 Schering Aktiengesellschaft Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
US20040138187A1 (en) 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
AR043444A1 (es) 2003-03-05 2005-07-27 Merck Frosst Canada Inc Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2
US20050008704A1 (en) 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
AU2005214167B2 (en) 2004-02-13 2008-08-07 Warner-Lambert Company Llc Androgen receptor modulators
EP1734918B1 (en) * 2004-04-14 2012-08-01 Eun-Joo Lee Pharmaceutical composition for treating hair loss and benign prostatic hyperplasia
JP2008189549A (ja) 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
ITMI20051695A1 (it) 2005-09-14 2007-03-15 Cosmo Spa Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
AU2014233572B2 (en) * 2007-08-03 2016-03-03 Cassiopea S.P.A. Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
JP5659232B2 (ja) * 2009-09-10 2015-01-28 トン、ヨウヂ アンドロゲン受容体アンタゴニストおよびその使用
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
US20140322148A1 (en) * 2011-11-25 2014-10-30 Adrianna Janell Jackson Oil Compositions and Methods for Increasing Hair Growth and/or Preventing Hair Loss
US9433268B2 (en) 2013-03-12 2016-09-06 Mark J. S. Ma Umbrella having a pivot joint to provide additional degrees of freedom of orientation of its canopy
CN105263469B (zh) * 2013-03-14 2018-11-02 阿勒根公司 包含比马前列素的局部组合物和利用其刺激毛发生长的方法
ITMI20132157A1 (it) 2013-12-20 2015-06-21 Cosmo Dermatos Srl Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle.
EP3108879A1 (en) * 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation

Also Published As

Publication number Publication date
ES3056907T3 (en) 2026-02-25
EP4650000A2 (en) 2025-11-19
JP2021169508A (ja) 2021-10-28
US20180169113A1 (en) 2018-06-21
BR112017027721A2 (pt) 2018-09-11
ZA201708173B (en) 2021-03-31
EP3108879A1 (en) 2016-12-28
KR102636936B1 (ko) 2024-02-16
RU2018101870A3 (es) 2019-11-25
US20190282589A1 (en) 2019-09-19
US11883415B2 (en) 2024-01-30
US10603327B2 (en) 2020-03-31
JP7196247B2 (ja) 2022-12-26
RU2018101870A (ru) 2019-07-23
KR20180019680A (ko) 2018-02-26
CN107979999A (zh) 2018-05-01
US20190374553A1 (en) 2019-12-12
RU2731564C2 (ru) 2020-09-04
JP6916744B2 (ja) 2021-08-11
CA2987701C (en) 2022-01-25
US20220193093A1 (en) 2022-06-23
JP2024069534A (ja) 2024-05-21
CN107979999B (zh) 2021-04-09
PT3310340T (pt) 2025-12-02
DK3310340T3 (da) 2025-12-15
LT3310340T (lt) 2026-02-10
EP3310340A1 (en) 2018-04-25
HRP20251498T1 (hr) 2026-03-13
US10980819B2 (en) 2021-04-20
RS67597B1 (sr) 2026-01-30
EP4650000A3 (en) 2026-02-25
JP2023027273A (ja) 2023-03-01
FI3310340T3 (fi) 2025-12-09
JP2018524325A (ja) 2018-08-30
US20200222429A1 (en) 2020-07-16
CA2987701A1 (en) 2016-12-29
MX2017017119A (es) 2018-08-01
JP7458464B2 (ja) 2024-03-29
US20240189324A1 (en) 2024-06-13
PL3310340T3 (pl) 2026-02-16
SMT202600032T1 (it) 2026-03-09
AU2016284935B2 (en) 2021-07-01
US11213531B2 (en) 2022-01-04
WO2016207778A1 (en) 2016-12-29
SI3310340T1 (sl) 2026-02-27
AU2016284935A1 (en) 2017-12-14
EP3310340B1 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
MX391040B (es) Formulacion de alta concentracion.
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
MX384948B (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos.
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CR20150462A (es) Inhibidores de erk y sus usos
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
JO3512B1 (ar) مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CR20150524A (es) Compuestos de heteroarilo y sus usos
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
EA201591962A1 (ru) Ингибиторы акк и их применение
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
CR20200089A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
CL2015002897A1 (es) Inhibidores de bace1
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции